Targeted intervention of eIF4A1 inhibits EMT and metastasis of pancreatic cancer cells via c-MYC/miR-9 signaling

Yuchong Zhao1†, Yun Wang1‡, Wei Chen1, Shuya Bai1, Wang Peng1, Mengli Zheng1, Yilei Yang1, Bin Cheng1* and Zhou Luan1*

Abstract

Background: Owing to the lack of effective treatment options, early metastasis remains the major cause of pancreatic ductal adenocarcinoma (PDAC) recurrence and mortality. However, the molecular mechanism of early metastasis is largely unknown. We characterized the function of eukaryotic translation initiation factors (eIFs) in epithelial-mesenchymal-transition (EMT) and metastasis in pancreatic cancer cells to investigate whether eIFs and downstream c-MYC affect EMT and metastasis by joint interference.

Methods: We used The Cancer Genome Atlas (TCGA) and Genome Tissue Expression (GTEx) databases to analyze eIF4A1 expression in PDAC tissues and further validated the findings with a microarray containing 53 PDAC samples. Expression regulation and pharmacological inhibition of eIF4A1 and c-MYC were performed to determine their role in migration, invasion, and metastasis in pancreatic cancer cells in vitro and in vivo.

Results: Elevated eIF4A1 expression was positively correlated with lymph node infiltration, tumor size, and indicated a poor prognosis. eIF4A1 decreased E-cadherin expression through the c-MYC/miR-9 axis. Loss of eIF4A1 and c-MYC decreased the EMT and metastasis capabilities of pancreatic cancer cells, whereas upregulation of eIF4A1 attenuated the inhibition of EMT and metastasis induced by c-MYC downregulation. Treatment with the eIF4A1 inhibitor rocaglamide (RocA) or the c-MYC inhibitor Mycro3 either alone or in combination significantly decreased the expression level of EMT markers in pancreatic cancer cells in vitro. However, the efficiency and safety of RocA alone were not inferior to those of the combination treatment in vivo.

Conclusion: Overexpression of eIF4A1 downregulated E-cadherin expression through the c-MYC/miR-9 axis, which promoted EMT and metastasis of pancreatic cancer cells. Despite the potential feedback loop between eIF4A1 and c-MYC, RocA monotherapy is a promising treatment inhibiting eIF4A1-induced PDAC metastasis.

Keywords: Eukaryotic translation initiation factor 4A1, c-MYC, Epithelial-mesenchymal transition, Rocaglamide, Mycro3

Introduction

Pancreatic ductal adenocarcinoma (PDAC) is universally one of the most lethal solid malignancies. Despite its relatively low incidence, PDAC remains the fourth leading cause of cancer-related death in developed countries [1, 2], with no significant changes in the mortality to incidence ratio in the past several decades and
Thus, novel therapeutics other than inhibitors target -inhibitors to dare [22, 23]. Considering that eIF4A is dis -the structure of c-MYC, there are few c-MYC targeted
promoting miR-9 expression [20, 21]. However, due to
c-MYC is a crucial regulator of EMT and metastasis by
and c-MYC is the most activated oncogenes [18, 19].
stream of eIFs, including c-MYC [17]. Overexpression
CLSH is a typical signature of various mRNAs down -
′-UTR). The -untranslated region (5
facilitates unbinding the complex long-sequence helix
-geting eIF4E were unsuccessful [15, 16]. eIF4A is the only
binding sites for oncogenic mRNA downstream of eIFs,
and c-MYC inhibitor Mycro3 were purchased from Med-
cyclopenta-b-benzofuran-type compound derived from
Traditional Chinese medicinal herbs have garnered increasing attention as a novel source of anticancer rem-
edies within the past decade. Rocaglamide (RocA) is a
cyclopenta-b-benzofuran-type compound derived from
and KRAS downstream (e.g., RAF, MEK, ERK, PI3K) have failed in phase I/II clinical trials [6–9].
Thus, novel therapeutics other than inhibitors target-
ing KRAS-associated kinases are urgently needed for
PDAC patients. Uncontrolled protein production is a common charac-
teristic of cancer cells, and it is also necessary for EMT and
metastasis [10]. Therefore, intervening to slow the hyperactive protein production has become a possible
therapeutic strategy for PDAC. Translation initiation reg-
ulated by eukaryotic translation initiation factors (eIFs)
is the most important rate-limiting step in translation
[11, 12]. Dysregulation of eIF expression and function is a hallmark of various types of cancers including PDAC;
the eIF4F heterotrimeric complex is the main factor facilitating mRNA translation. Meanwhile, eIF4F activity
is largely regulated by RAS signaling, which further indicates that eIF could play an important role in PDAC [13,
14]. The eIF4F complex is composed of the scaffold pro-
tein eIF4G, cap-binding protein eIF4E, and ATP-depend-
ent DEAD-box RNA helicase eIF4A. Previous studies
typically targeted eIF4E to inhibit EMT and metastasis of
cancer cells, because eIF4E is generally overexpressed in
multiple cancers. However, recent studies demonstrated that there are eIF4E-independent and eIF4A-dependent
binding sites for oncogenic mRNA downstream of eIFs,
including c-MYC, which could explain why studies target-
ing eIF4E were unsuccessful [15, 16]. eIF4A is the only
 regulatory enzyme-catalytic factor in the eIF family, and
facilitates unbinding the complex long-sequence helix
(CLSH) in mRNA 5′-untranslated region (5′-UTR).
The CLSH is a typical signature of various mRNAs down-
stream of eIFs, including c-MYC [17]. Overexpression of
c-MYC is a carcinogenesis driver for multiple cancers
and c-MYC is the most activated oncogenes [18, 19].
c-MYC is a crucial regulator of EMT and metastasis by
promoting miR-9 expression [20, 21]. However, due to
the structure of c-MYC, there are few c-MYC targeted
inhibitors to dare [22, 23]. Considering that eIF4A is dis-
ensible for c-MYC translation, we hypothesized that
interfering with eIF4A function could be an effective way
to inhibit c-MYC.

Materials and methods
Cell culture and reagents
An immortalized pancreatic ductal epithelial cell line
(HPDE) and pancreatic cancer cell line (Canpan-2) were
obtained from the Cell Bank of the Chinese Academy of
Sciences (Shanghai, China), and the pancreatic cancer
cell lines AsPC-1, BxPC-3, and Panc-1 were purchased
from the American Type Culture Collection (VA, USA).
Cells were cultured in RPMI-1640 medium (GIBCO, NY,
USA) supplemented with 10% fetal bovine serum (FBS,
GIBCO) and 1% penicillin/streptomycin (Invitrogen) at
37 °C in a 5% CO2 incubator. The eIF4A inhibitor RocA
and c-MYC inhibitor Mycro3 were purchased from Med-
ChemExpress (MCE, USA).

Patient’ follow-up and specimens collection
This study was approved by the Ethics Committee of
Tongji Hospital of Tongji Medical College, Huazhong
University of Science and Technology (TJ-IRB20210927).
All patients were completely informed of the possible use of their clinical information/specimens and we obtained full consent for the study. The cohort comprised 53 patients with PDAC who underwent surgical resection from 2009 to 2013 at the Department of Pancreatic and Hepatobiliary Surgery, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology (Wuhan, China). All PDAC specimens were verified by pathologists and met the criteria set by the American Pancreatic Association. None of the patients underwent preoperative neoadjuvant therapy. The patients were evaluated every 3 months during the first 3 years and every 6 months thereafter by physicians who were blinded to the study parameters. Follow-up data were summarized at the end of December 2020. To evaluate the prognostic role of elf4A1, tissue microarrays of the 53 PDAC samples were collected for further analysis.

Immunohistochemistry (IHC)

IHC staining with the elf4A1 antibody (Abcam ab31217) was performed to detect the protein expression level. Image (http://imagej.nih.gov/ij) IHC profiler (http://sourceforge.net/projects/ihcprofiler) was used to assess IHC staining of the microarray based on two categories: staining intensity and percentage of staining. The staining intensity was scored as follows: negative (0 points), weak-positive (1 point), positive (2 points), and strong-positive (4 points). The protein expression level was quantified by multiplying the staining intensity and corresponding extents of positive staining (n%: percentage of positive areas to the whole areas). Then we divided the patients into two groups (score < 50, low expression; score > 50, high expression) and performed subsequent survival analysis. The IHC staining results were reassessed by two independent pathologists who were blinded to this study.

Immunofluorescence

Paraformaldehyde fixed samples were washed 3 times with ice-cold PBS for 3 min each time and then incubated in 10% donkey serum in PBS for 20 min. Subsequently, the samples were incubated with the elf4A1 antibody (Abcam ab31217) in PBS at 4 °C overnight. After washing, fluorochrome-conjugated secondary antibodies (1:400, Alexa Fluor® 488 donkey anti-rabbit IgG) were used, and then the samples were treated with DAPI. The fluorescence was visualized under an Olympus microscope.

Lentiviral transduction

The lentivirus pLVX-Puro (Addgene) was obtained from DesignGene Biotechnology (Shanghai, China) and used to clone shRNA sequences. The vectors were designated Lv-elf4A1 (elf4A1-1, 5′-CACACTGGACTAGTGGATTCCC-3′; elf4A1-2, 5′-AGTCACTTGAGACTTGGATGAGGTCAGCAATCTGGAG-3′), Lv-sh-c-MYC (c-MYC-1, 5′-GCTCACCAACAGGACTATG-3′; c-MYC-2, 5′-GCTTACCACTCAGGAGATCTG-3′; c-MYC-3, 5′-GGAACGACGACAGCAGTGGAG-3′) and Lv-sh-control (empty vector). The lentivirus plasmid and packaging plasmids were transfected into pancreatic cancer cells with transfection reagent (Lipofectamine®3000, Thermo Fisher Scientific) in OPTI-MEM media (Invitrogen, MA, USA). Lentiviral infection of the target cells was performed in cell culture medium containing 5 μg/ml polybrene (Sigma H9268), and infected cells were selected with 2.5 μg/ml puromycin for follow-up experiments.

Quantitative real-time PCR (RT-qPCR)

cDNA was created with PrimeScript™ RT reagent Kit Perfect Real Time, (Takara, RR037A) according to the manufacturer’s protocol. Quantitative PCR was performed on a StepOne Real-Time System (Thermo Fisher Scientific) using TB Green® Premix EX Taq™ (Takara, RR820a) according to the manufacturer’s protocol. Melting curve analysis was performed and the amplification plots were evaluated by SDS 1.9.1 software (Applied Biosystems, MA, USA). The 2−ΔΔCt method was used to determine relative fold changes in target gene expression from replicate samples. The bulge-loop primer for miR-9 was provided by RioBIO (Guangzhou, China).

Western blot

Western blot analysis was performed as described previously [28]. The primary antibodies targeted elf4A1 (Abcam ab31217), c-MYC (Abcam ab32072), snail (Abcam ab216347), E-cadherin (Abcam ab40772), and β-actin (Abcam, ab8226). Protein bands were visualized using Beyo ECL Plus and quantified with ImageJ.

Transient transfection

Cells were transfected with scramble siRNA or siRNA targeting elf4A1 (siRNA1, 5′-GAGTAACTGGAATGAGATT-3′; siRNA-2, 5′-TCCAGCAGCGAGGCAATTCTC-3′; siRNA-3, 5′-CGTTGGTTTGATATGCTTA-3′) and c-MYC (siRNA-1, 5′-GAGGAGACATGTGAACCA-3′; siRNA-2, 5′-GGGTCAGGGGAGATAAGTGG-3′; siRNA-3, 5′-GCACAGACCTTCATCAAA-3′) with Lipofectamine®3000 (Thermo Fisher Scientific) and OPTI-MEM (Invitrogen, MA, USA) according to the manufacturer’s protocol. elf4A1-siRNA-1 and c-MYC-siRNA-3 were the most effective in knocking down their respective targets and were used for further analysis. Cells were transfected with CV567 empty vector, pcDNA3.1-elf4A1 (P1, 5′-CACACTGGACTAGTGGATTCCC-3′; elf4A1-2, 5′-AGTCACTTGAGACTTGGATGAGGTCAGCAATCTGGAG-3′).
GTGGATCCGCCCATGTCTGCGAGCCAGGAT
TCCC-3') or pcDNA3.2-c-MYC plasmids (P1, 5'-CAC
ACTGGACTGATGGATCCGCACCATGGATTT
TTTCGGGTAGTGG-3') using the transfection rea-
gent Lipofectamine®3000 (Thermo Fisher Scientific) and
OPTI-MEM (Invitrogen, MA, USA) according to the
manufacturer's protocol.

In vitro migration and invasion assay
Cell migration and invasion were analyzed using Tran-
well chambers (8-μm pore size; Millipore, Billerica,
MA, USA) with and without a Matrigel (BD Biosciences,
San Jose, CA, USA) matrix in the upper chamber. Four
groups of AsPC-1 cells were pretreated in DMSO, RocA
(100 nM), Mycro3 (5000 nM), and combination treat-
ment solutions for 4 h. Then the cells were seeded FBS-
free culture medium in the upper chamber with 10% FBS
culture medium in the lower chamber as a chemoattract-
ant. After 28 h (Migration) or 32 h (Invasion) of incuba-
tion, cells on the lower surface of the membrane were
washed with PBS, fixed in 4% methanol, and stained with
a 0.4% crystal violet solution. Photographs of three ran-
domly selected fields of the fixed cells were captured and
cells were counted. The experiments were repeated inde-
dependently three times.

CCK8 assay
The sensitivity of cells to RocA and Mycro3 either or in
combination was measured by CCK8 assay. Cells were
seeded in a 96-well plate at density of 1000 cells per
well and then treated with the treatment concentrations
(RocA, 100 nM; Mycro3, 5000 nM). After the cells were
attached. Then incubated for 4 h, replace fresh 1640 cul-
ture medium and cell counting kit-8 (CCK8, promoter,
China) to each well according to the manufacturer's protocoll, incubated at 37 °C for 2 h. Absorbance was
measured at 450 nm using a microplate reader (Thermo
Scientific).

Establishment of a metastatic mouse model
Animal experiments were approved by the Ethics Com-
mitee of Tongji Hospital of Tongji Medical College,
Huazhong University of Science and Technology (TJH-
2020100007). Four-week-old female severe combined
immune deficiency (SCID) mice (Charles River Co.,
Beijing) were maintained in a specific pathogen-free
(SPF) environment. To establish the metastatic mouse
model in vivo, 2 × 10⁶ AsPC-1 cells in 200 μl were
intravenously injected via caudal vein into each ani-
mal. Small animal imaging (Spectral Imaging LagoX)
was performed every 3 days after cell injection and
the mice were randomly divided into different groups
(5/ group). RocA (MCE, USA) was administered daily
by intraperitoneal injection (5 mg/kg/d, 3 mg RocA
dissolved in 30 μl DMSO, 600 μl PEG300 and 75 μl
TWEEN-80 successively, and then adjusted to a volume
of 1.5 ml with normal saline) every day originally [26],
then adjusted to 2.5 mg/kg/d once on an alternate day.
Mycro3 was administered intragastrically (100 mg/
kg/d, 25 mg mycro3 dissolved in 2.5 ml of 0.5% methyl-
cellulose solution and subject to ultrasonication) [29].
Control mice were treated with intragastric 200 μl of
methylcellulose solution daily and 100 μl of methyl-
cellulose solution via intraperitoneal injection once
on an alternate day. When the total body weight loss
was > 20%, the mice were sacrificed by cervical verte-
bra dislocation under deep sedation conditions using
70 mg/kg pentobarbital sodium (peritoneal injection).

Subcutaneous xenografts in nude mice
Four-week-old nude mice were obtained from HFK
Bioscience Ltd (Beijing, China) and maintained in SPF
conditions. AsPC-1 cells (5.0 × 10⁶) suspended in a
100 μl solution comprising equal volumes of medium
and matrix gel were subcutaneously implanted into the
right flanks of 6-week-old female nude mice. When the
tumors had reached a volume of approximately 60–90
mm³, the mice were then randomly divided into two
groups. The treatment group received an intraperi-
toneal injection of RocA (previously adjusted dose),
whereas the control group received cosolvent injection
alone (n = 4, the treatments were carried out once daily
for 28 days. The tumor volumes and total body weight
of the animals were measured twice a week. The tumor
volumes (mm³) were calculated with the following for-
"mula: V = LS²/2 (where L is the longest diameter and S
is the shortest diameter). At the end of the experiment,
the mice were sacrificed and the tumors were har-
vested for western blot analysis. The mice were sacri-
ficed 4 weeks after implantation by cervical dislocation
under deep sedation conditions using 70 mg/kg pento-
barbital sodium (peritoneal injection).

Statistical analysis
The data are representative of at least three independent
experiments or multiple independent mice as indicated.
The patient characteristics were summarized as the
mean±standard deviation (SD) for normally distributed
continuous variables, median with interquartile range for
continuous variables with a skewed distribution, and fre-
cquency (percentage) for categorical variables. All analy-
"ses were performed using R (http://www.R-project.org,
version 3.5.2) with a two-sided significance threshold of
P<0.05.
Results
eIF4A1 was highly expressed in PDAC and predicted a poor prognosis

First, we analyzed eIF4A1 expression across multiple cancers using data from Gene Expression Profiling Interactive Analysis (GEPIA, http://geopia.cancer-pku.cn/). eIF4A1 was highly expressed in multiple cancer types, including pancreatic adenocarcinoma, thymoma, glioblastoma multiforme, diffuse large B cell lymphoma, and testicular germ cell tumors (Fig. 1a). To evaluate the expression of all eIF family members in pancreatic adenocarcinoma, we analyzed the RNA-seq data from the TCGA and GTEx databases. Two samples were deleted after data quality control, resulting in 179 pancreatic tumor tissues and 169 normal pancreatic tissues. We ranked the differential expression of all eIFs (Fig. 1b) and the results showed that the expression level of eIF4A1 in pancreatic tumor tissues was significantly higher than that in normal tissues (Fig. 1c).

Subsequently, we analyzed the prognostic role of eIF4A1 in PDAC patients. Immunofluorescence results indicated that eIF4A1 was mainly localized in the cytosol (Fig. 1d), which was consistent with its function in assisting translation initiation. The fluorescence intensity in the more aggressive AsPC-1 cell line was significantly higher than that in Capan-2 cells. We used IHC to detect eIF4A1 expression in a tissue microarray comprising samples from 53 patients with pathologically confirmed PDAC from 2009 (Fig. 1e). The results indicated that patients with high eIF4A1 expression had a poor prognosis, and the median overall survival of patients with high eIF4A1 expression was significantly shorter than that of patients with low eIF4A1 expression (6.0 months vs. 9.0 months, HR = 2.10, 95% CI: 1.44–5.24, P = 0.0061) (Fig. 1f). Furthermore, we examined the correlations between eIF4A1 expression and multiple clinical features (Table 1, *P < 0.05; chi-square or Fisher’s exact test). Importantly, we found that a high level of eIF4A1 expression was significantly correlated with tumor size and lymph node metastasis. In summary, these results showed that eIF4A1 was highly expressed in pancreatic adenocarcinoma tissues, and high expression of eIF4A1 suggested a poor prognosis. The eIF4A1 expression was positively correlated with lymph node metastasis which is a major mechanism of cancer cell metastasis.

eIF4A1 targeted c-MYC to regulate metastasis in pancreatic cancer cells

To elucidate the mechanism by which eIF4A1 regulates the biological behavior of tumor cells, we searched...
Table 1 Correlation between eIF4A1 expression and clinical characteristics of PDAC patients

| Clinical characteristics                | High-eIF4A1   | Low-eIF4A1  | P-value |
|----------------------------------------|--------------|-------------|---------|
| Age, mean ± SD, years                  | 66.04 ± 9.69 | 64.10 ± 10.07 | 0.482 |
| Male, n (%)                            | 13 (56.53%) | 21 (70.00%) | 0.311 |
| Overall survival, median, months       | 6.0 (4.0, 9.0) | 9.0 (8.0, 15.5) | 0.006b |
| Differentiation status                 |              |             | 0.523 |
| Well differentiated                    | 11 (20.75%) | 17 (32.08%) | |
| Moderately to poorly differentiated    | 12 (22.44%) | 13 (24.53%) | |
| Tumor size, mean ± SD, cm             | 4.57 ± 1.40  | 3.75 ± 1.28 | 0.032b |
| Recurrences, n (%)                    | 17 (73.91%) | 20 (66.67%) | 0.569 |
| Location                               |              |             | 0.267 |
| Head, n (%)                            | 15 (28.30%) | 18 (33.96%) | |
| Body/tail, n (%)                       | 7 (13.21%)  | 20 (37.74%) | |
| Diffusion involvement, n (%)           | 1 (1.89%)   | 2 (3.77%)   | |
| TNM stagea                             |              |             | 0.77 |
| I–II stage, n (%)                      | 14           | 24          | |
| III–IV stage, n (%)                    | 9            | 5           | |
| Lymph node metastasis, n (%)          | 14 (63.64%) | 10 (35.71%) | 0.0498* |
| Vascular infiltration, n (%)          | 10 (43.48%) | 3 (10.00%)  | 0.272 |

a NCCN Version 3.2019 pancreatic adenocarcinoma
b P < 0.05, significant difference

correlated with eIF4A1 expression in PDAC and across various cancer types (Fig. 2b; n = 44, r = 0.5041, P = 0.0005, Spearman correlation; Additional file 2: Fig. S2).

Gene Ontology (GO) analysis using ribosome-sequencing data revealed that the DEPs were significantly enriched in the GO terms for 497 biological processes (BPs), 56 cellular components (CCs), and 48 molecular functions (MFs) (Fig. 2c). We concluded that the DEPs were enriched in functions critical for metastasis, including signal transduction, cytoskeleton, lymph-angiogenesis, and cell junctions. Gene set enrichment analysis (GSEA) performed with ribosomal profiling showed that the enrichment of EMT-related gene sets was reduced significantly after CR-31-B treatment (Fig. 2d). These results indicated that eIF4A1 could target c-MYC to regulate the biological behaviors of pancreatic cancer cells.

eIF4A1 promoted EMT and metastasis through c-MYC/miR-9 signaling

Recent studies have demonstrated that c-MYC promotes EMT by upregulating the expression of miR-9, which can competitively bind with E-cadherin encoding sequence of CDH1 and subsequently drive EMT [20, 30]. Before exploring the role of eIF4A1 and c-MYC in the regulatory effect in pancreatic cells, we analyzed eIF4A1 expression in the pancreatic cancer cell lines Panc-1, Capan-2, AsPC-1, and MiaPaca-2, and in the normal pancreatic ductal epithelial cell line HPDE. Western blot analysis showed that eIF4A1 was notably more highly expressed in the aggressive pancreatic cancer cell line AsPC-1 and relatively less expressed in the indolent Capan-2 cell line and normal HPDE cells (Fig. 3a). Therefore, we selected AsPC-1 and Capan-2 for the subsequent experiments. We knocked down eIF4A1 and c-MYC expression in AsPC-1 cells (eIF4A1 siRNA, c-MYC siRNA) and overexpressed eIF4A1 and c-MYC in Capan-2 cells (pcDNA3.1-eIF4A1, pcDNA3.2-myc). Western blot and qRT-PCR showed that eIF4A1 knockdown in AsPC-1 cells decreased the expression of EMT-related genes (c-MYC, snail, and miR-9) and increased the expression of E-cadherin (Fig. 3b). c-MYC knockdown resulted in the same changes in expression (Figure, 3c); however, repressing c-MYC expression did not influence eIF4A1 expression. Accordingly, eIF4A1 and c-MYC overexpression in Capan-2 cells showed expression patterns opposite of those observed in the knockdown experiments (Fig. 3d, e). Transwell migration and invasion assays revealed that AsPC-1 cells with eIF4A1 and c-MYCs knockdown displayed significantly lower migratory and invasive abilities (Fig. 3f), whereas these abilities were significantly increased in eIF4A1 and c-MYC overexpressing Capan-2 cells compared to those in control cells.
Based on the changes in the expression of EMT-related molecules and the changes in the cells' migratory and invasive capabilities, these results indicated that eIF4A1 could promote EMT by targeting c-MYC/miR-9 signaling.

**Overexpression of eIF4A1 increased the invasive, migratory, and metastatic capabilities of MYC-knockdown AsPC-1 cells in vitro and in vivo**

The relationship between eIF4A1 and c-MYC is not linear, recent studies revealed that overexpression of c-MYC could increase the level of eIF4A1 expression [15, 31]. To further explore the regulatory interactions between eIF4A1 and c-MYC, lentivirus was used to regulate eIF4A1 and c-MYC expression in AsPC-1 cells. There were four groups: (1) e-U-M-D sequential regulation group (overexpression of eIF4A1 expression (Lv- eIF4A1) followed by c-MYC knockdown (Lv-sh-c-MYC)); (2) e-U group (overexpression eIF4A1 (Lv- eIF4A1)); (3) M-D group (c-MYC knockdown (Lv-sh-c-MYC)); (4) vector group (Lv-sh-control).

Western blots showed that E-cadherin expression was significantly decreased in e-U AsPC-1 cells and significantly increased in the M-D AsPC-1 cells. The E-cadherin expression in e-U-M-D AsPC-1 cells was between that in the e-U and M-D cells but was still higher than the level in the vector group cells (Fig. 4a). Consistent with the trends of western blot results, Transwell migration and invasion assays showed that the migratory and invasive abilities of e-U-M-D cells were superior to those of the M-D cells but was still higher than the level in the vector group cells (Fig. 4a). In vivo, the metastatic potentials of these cells were examined using a mouse metastasis model via caudal vein injection. The results revealed that the luminescence intensity of e-U-M-D cells was significantly higher than M-D group cells ($1.008 \pm 1.10$ vs. $5.387 \pm 9$, $P=0.0349$), accordingly weaker to the e-U group cells ($1.008 \pm 1.10$ vs. $2.410 \pm 4.29$, $P=0.2369$) (Fig. 4c).
Fig. 3 eIF4A1 targeted c-MYC to promote EMT in pancreatic cells. a Western blot results show that eIF4A1 was highly expressed in the aggressive AsPC-1 cells and minimally expressed in the indolent Capan-2 cells. b, c Downregulation of eIF4A1 or c-MYC increased the expression of E-cadherin but decreased the expression of snail and miR-9. Downregulation of eIF4A1 decreased c-MYC expression, but the changes in c-MYC expression did not influence the expression of eIF4A1. d, e Upregulation of eIF4A1 or c-MYC decreased the expression of E-cadherin but increased the expression of snail and miR-9. Upregulation of eIF4A1 increased c-MYC expression, but the changes in c-MYC expression did not influence the expression of eIF4A1. f Knockdown of eIF4A1 or c-MYC impaired the migratory and invasive capabilities of AsPC-1 cells. g Overexpression of eIF4A1 or c-MYC enhanced the migratory and invasive capabilities of Capan-2 cells. *P < 0.05, **P < 0.01, ***P < 0.001

Fig. 4 Sequential regulation of eIF4A1 and c-MYC expression in vitro and in vivo. a E-cadherin expression in AsPC-1 cells in the e-U-M-D group was between that in AsPC-1 cells in the e-U group and that in AsPC-1 cells in the M-D group. b The migratory and invasive capabilities of e-U-M-D AsPC-1 cells were significantly stronger than those of M-D cells. c The metastatic capabilities of e-U-M-D cells were between those of e-U and M-D cells in vivo. *P < 0.05, **P < 0.01, ***P < 0.001
Collectively, the in vitro and in vivo results revealed that the level of EMT and metastatic capabilities of e-U-M-D cells were between those of the e-U cells and M-D cells. These results indicated that overexpression of eIF4A1 expression could attenuate the inhibition of MYC-downregulated pancreatic cancer cells of EMT and metastasis.

**RocA alone was not inferior to RocA plus Mycro3 joint intervention inhibiting EMT and metastasis in vitro and in vivo**

Our previous studies demonstrated that c-MYC was not the only target of eIF4A1 to promote EMT and metastasis. When c-MYC is repressed, eIF4A1 might exert a pro-EMT effect through other pathways to compensate for this inhibition. Considering the complex feedback relationship between eIF4A1 and c-MYC, we implemented a combination treatment comprising RocA (an eIF4A1 inhibitor) and Mycro3 (a c-MYC inhibitor) to explore whether the combination is superior to either monotherapy.

To select the optimal drug concentration, we conducted a series of concentration gradient experiments. The western blot results showed that eIF4A1 expression decreased significantly in response to 100 nM RocA and that c-MYC expression decreased significantly in response to 5000 nM Mycro3 (Fig. 5a). Crystal precipitates formed when the concentrations increased beyond the value in subsequent experiments; thus, we selected 100 nM RocA and 5000 nM Mycro3 in subsequent experiments. We established 4 treatment groups [(1) RocA + Mycro3; (2) RocA; (3) Myro3; (4) DMSO control] and compared their safety and efficacy. Western blots and qRT-PCR showed that all 3 intervention methods significantly increased E-cadherin expression and decreased c-MYC expression in AsPC-1 cells (Fig. 5b). Compared with the DMSO treated cells, CCK8 assay showed that pretreatment with RocA and Mycro3 either alone or in combination did not affect the death ratio of AsPC-1 cells (Fig. 5c). However, all 3 intervention methods remarkably decreased the migratory and invasive abilities and methods decreased the EMT level of pancreatic cancer cells compared with the control group (Fig. 5d; Additional file 3: Fig. S3). However, there was no statistically significant difference among the 3 groups.

To examine the efficiency and safety of the treatments in vivo, we injected mice with AsPC-1 cells via caudal vein. We found that the mortality rates of the RocA group (40.0%) and combination group (62.5%) were relatively high. Evaluation of mice after sacrifice showed multiple cases presenting nonocclusive intestinal dilation. Considering the possible intolerance due to the high dose of RocA administered, we decreased the dosage from 5 mg/kg/d qd to 2.5 mg/kg/d once on alternate days (still administered via intraperitoneal injection), while the dosage of Mycro3 remains 100 mg/kg/d qd (administered intragastrically). The mice tolerated the modified regimen better without more deaths. The luminescence intensity from the RocA group was significantly weaker than that of the control group (1.393e + 9 vs. 2.707e + 9, \( P=0.0474 \)). However, there were no significant differences in luminescence intensity between the control and both the Myro3 and combination groups (Fig. 5e). Taken together, these data demonstrated that the modified of RocA monotherapy exerted an obvious antimetastatic effect, superior to Mycro3 or the combination treatment.

To further evaluate the efficacy of RocA, we used a subcutaneous xenograft nude mouse model. Two-way ANOVA indicated that the tumor volumes of the RocA group were significantly smaller than those of the control group \( (P<0.0001) \) (Fig. 5f) which suggested that RocA notably suppressed tumor growth. Western blot analysis showed that RocA markedly decreased the expression of eIF4A1, c-MYC, and snail and increased the expression of E-cadherin (Fig. 5g) in vivo.

**Discussion**

Various oncogenes associated with PDAC, including KRAS and its downstream kinases cannot be targeted because of their specific molecular structures \([23, 32]\). However, targeting translation has been an alternative approach for cancer treatment. Protein production in PDAC was verified to be hyperactive both in vivo and in organoids \([33]\), eIF4A, which participates in the assembly of eIF4F, is the nexus for translational regulation \([13, 34]\). Unlike KRAS, eIF4A can be targeted, and the curative effects of targeting eIF4A have been validated in several hematological malignancies \([25, 35]\), positioning this molecule as an alternative treatment for PDAC. Recent studies revealed that eIF4A1 inhibition could significantly repress the tumor growth by remodeling metabolism and DNA replication \([36, 37]\). Here, we present a novel strategy for inhibiting EMT and metastasis in pancreatic cancer cells via c-MYC/miR-9 signaling.

Our previous study demonstrated that targeting eIF4A could significantly decrease the lung metastasis of pancreatic cancer cells in vivo \([26]\). Here we further elucidated the mechanism by which eIF4A promotes EMT and metastasis and verified that eIF4A1 was correlated with a worse prognosis. Considering the complex long-sequence 5'-UTR structure of c-MYC mRNA, we showed that the regulation of c-MYC expression was highly dependent on eIF4A. Depletion of eIF4A1 significantly decreased the expression levels of c-MYC and EMT markers in vitro. Overexpression of eIF4A1 induced a decrease in E-cadherin expression through the c-MYC/
Fig. 5  RocA and Mycro3 suppressed EMT and metastasis in pancreatic cancer cells in vitro and in vivo.  

**a** The suitable concentrations for treatment were initially determined to be 100 nmol/L (RocA) and 5000 nmol/L (Mycro3).  

**b** Treatment with 100 nmol/L RocA and 5000 nmol/L Mycro3, and either alone or in combination significantly inhibited the expression of miR-9 and c-MYC in AsPC-1 cells.  

**c** AsPC-1 cells were treated with DMSO, RocA (100 nM), Mycro3 (5000 nM), and combination treatment for 4 h and evaluated by CCK8 assay. It showed that there were no significant differences of the death ratio among each treatment group.  

**d** Treatment with 100 nmol/L RocA and 5000 nmol/L Mycro3 either alone or in combination significantly decreased the migratory and invasive capabilities of AsPC-1 cells. There were no significant differences among the treatment groups.  

**e** RocA significantly decreased the metastasis level of AsPC-1 cells in vivo whereas Mycro3 and the combination treatment did not.  

**f** RocA significantly suppressed subcutaneous tumor xenograft growth.  

**g** Western blot results showed that RocA notably decreased the expression of eIF4A1, c-MYC, and snail, but increased the expression of E-cadherin in subcutaneous tumor grafts. *P < 0.05, **P < 0.01, ***P < 0.001, NS: no statistical significance.
miR-9 axis. Furthermore, depletion of either eIF4A1 or c-MYC significantly decreased the EMT level and metastasis in vitro and in vivo, and vice versa. However, regulating translation is extremely complicated. c-MYC is likely not the only target for eIF4A1 to promote EMT and metastasis and it was reported that c-MYC overexpression could further upregulate eIF4A1 [31, 38]. In this study, we found that eIF4A1 overexpression rescued the diminished EMT and metastasis capabilities of c-MYC knockdown pancreatic cancer cells in vitro and in vivo. Nevertheless, the compensation for c-MYC depletion was incomplete, as the metastatic capabilities of e-U-M-D cells were significantly weaker than those of e-U cells whereas stronger than those of M-D cells. This result indicated that even if there are other targets of eIF4A1, c-MYC still plays a vital role in eIF4A-mediated EMT and metastasis.

Similar to KRAS, c-MYC has traditionally been deemed an “undruggable” target. However, Mycro3 is a novel anti-MYC compound inhibits c-MYC activity through MYC dimerization [23, 39]. As previously mentioned, the relationship between eIF4A and c-MYC was not simply unidirectional; thus, simultaneously targeting eIF4A and c-MYC was employed, and the efficacy and safety of this regimen were evaluated. Our work demonstrated that RocA or Mycro3 either alone or in combination notably repressed the EMT level in vitro. However, the combination treatment did not show any superiority to the monotherapies. Similar to the in vitro results, RocA was the only reagent that exerted a significant antimetastatic effect in vivo among the two monotherapy and combination treatment. The reason behind this result is still unknown, but we can speculate from preparatory experiments that combining RocA and Mycro3 increased the risk of death, as the mice were not tolerant of the original dose. The dose of RocA in previous studies ranged from 1.4 mg/kg once on an alternate day to 5 mg/kg daily for cancer treatment [26, 35, 40–45], which was quite extensive. Further toxicity analysis is required to elucidate the most accurate treatment dose selection. All previous studies using RocA for pancreatic cancer treatment was administered 5 mg/kg/d [26, 41]. However, our study showed that mid-dose 2.5 mg/kg every other day RocA monotherapy also dramatically suppressed eIF4A-mediated pancreatic cancer cell metastasis.

**Conclusions**

Collectively, we demonstrated that eIF4A1 overexpression downregulated E-cadherin expression through the c-MYC/miR-9 axis (Fig. 6), which promoted EMT and the metastasis of pancreatic cancer cells in vitro and in vivo. In addition, ectopic expression of eIF4A1 partially rescued the inhibition of EMT and metastasis mediated by c-MYC-depletion. Moreover, RocA monotherapy

---

**Fig. 6** eIF4A1 promotes EMT in pancreatic cancer cells via c-MYC/miR-9 signaling
was superior to the combination treatment at the current dose, possibly due to intolerance. Our data indicated that eIF4A1 is a satisfactory biomarker for PDAC prognosis, and targeting eIF4A1 provides a promising therapeutic strategy for overcoming PDAC metastasis.

Abbreviations
PDAC: Pancreatic ductal adenocarcinoma; eIF: Eukaryotic translation initiation factor; EMT: Epithelial mesenchymal-transition; ROCa: Rogaclamide; TCGA: The Cancer Genome Atlas; GTEX: Genome tissue expression; 5'-UTR: 5'-Untranslated region; FC: Fold change; FDR: False discovery rate; DEP: Differential expressed protein.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12935-021-02390-0.

Additional file 1: Fig. S1. SDS-PAGE of eIF4A1-knockdown AsPC-1 cells. The protein abundance at 49 kDa (the molecular weight of c-MYC) remarkably decreased after the knockdown of eIF4A1.

Additional file 2: Fig. S2. Analysis of the correlation of eIF4A1 and c-MYC using data from TCGA and GTEX databases. (a): The expression of eIF4A1 and c-MYC in tumor tissues and normal tissues of PDAC patients were analyzed. c-MYC is positively correlated with eIF4A1 (r = 0.475, P = 2.26e-16, Spearman correlation). (b): c-MYC and eIF4A1 are positively correlated in most cancer types including PDAC.

Additional file 3: Fig. S3. Fluorescence in situ hybridization (FISH) assay showed that treatment with 100 nM RoCA for 12 h significantly decreased the miR-9 expression in AsPC-1 cells.

Acknowledgements
We sincerely thank all staff from the Tongji Hospital, Tongji Medical College, HUST for their effort in project execution. We also thank the statistical staffs (Ping Yin, Chang Shu) at the Department of Epidemiology and Biostatistics, School of Public Health, Tongji Medical College, HUST and Hepatic Surgery Centre, Tongji Hospital, Tongji Medical College, HUST and support from Shoujiang Tang, University of Mississippi Medical Center. And we deeply thank the supportive data uploaded by Karina Chan et al. (https://doi.org/10.1038/s41467-019-13086-5, GSE120159) from Columbia University Medical Center.

Authors' contributions
B.C. and L.Z. designed the study and performed data analysis. Y.Z. and Y.W. performed acquisition of data. Y.Z. drafted the manuscript. W.Y. provided critical revision of the manuscript for important intellectual content. W.C., S.B., Y.Z., Y.W., W.Y., M.L., Y.Z. and W.P. approved the manuscript.

Funding
This work is supported by the National Natural Science Foundation of China, granted number: No. 81802427), and the Wuhan Science and Technology Bureau granted number: No. 20190207010114310.

Availability of data and materials
The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
The study concerning the clients’ right to privacy. The study was approved by the Ethical Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology and was conducted according to the principles of the Declaration of Helsinki. Written informed consent was obtained from the subject, and his study considered declaration of Helsinki as a statement of ethical principles. Informed consent was obtained from all patients.

Consent for publication
Not applicable.

Competing interests
Dr. Yuchong Zhao, Yun Wang, Wei Chen, Shuya Bai, Wang Peng, Mengli Zheng, Yilei Yang, Bin Cheng, and Zhou Luan have no conflicts of interest or financial ties to disclose.

Author details
1Department of Gastroenterology and Hepatology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Avenue No. 1095, Wuhan 430030, China. 2Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Jianshe East Road No. 1, Zhengzhou, China.

Received: 14 September 2021   Accepted: 3 December 2021
Published online: 14 December 2021

References
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;70(4):333–54.
2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33.
3. Pereira SP, Oldfield L, Nye A, Hart PA, Keane MG, Pandol SJ, et al. Early detection of pancreatic cancer. Lancet Gastroenterol Hepatol. 2020. https://doi.org/10.1016/S2548-1253(19)30416-9.
4. Rhim AD, Mirek ET, Aiello NM, Bailey JM, McAllister F, et al. EMT and dissemination precede pancreatic tumor formation. Cell. 2012;148(1–2):349–61.
5. Magliano MPJ, Logsdon CD. Roles for KRAS in pancreatic tumor development and progression. Gastroenterology. 2013;144(6):1220–9.
6. Hendifar AE, Blais EM, Ng C, Thach D, Gong J, Sohal D, et al. Comprehensive analysis of KRAS variants in patients (pts) with pancreatic cancer (PDAC): clinical/molecular correlations and real-world outcomes across standard therapies. J Clin Oncol. 2020;38(15_suppl):4641.
7. Varga A, Soria JC, Hollebecque A, LoRusso P, Bendell J, Huang SMA, et al. A first-in-human phase I study to evaluate the BRK1/2 inhibitor GDC-0994 in patients with advanced solid tumors. Clin Cancer Res. 2020;26(6):1229–36.
8. Van Cutsem E, Hidalgo M, Canon JL, Macarulla T, Bazin I, Poddubskaya E, et al. Phase II/III trial of panitumumab plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma. Int J Cancer. 2018;143(8):2053–64.
9. Bedard PL, Tabernero J, Janku F, Wainberg ZA, Paz-Ares L, Vansteenkiste J, et al. A phase Ib dose-escalation study of the oral pan-PI3K inhibitor Buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. Clin Cancer Res. 2015;21(4):730–8.
10. Silvera D, Formenti SC, Schneider RJ. Translational control in cancer. Nat Rev Cancer. 2010;10(4):254–66.
11. Clemens MJ. Targets and mechanisms for the regulation of translation in malignant transformation. Oncogene. 2004;23(18):3180–8.
12. Raza F, Waldron JA, Le Quesne J. Translational dysregulation in cancer: eIF4A isoforms and sequence determinants of eIF4A dependence. Biochem Soc Trans. 2015;43:1227–33.
13. Boussemart L, Malka-Mahieu H, Girault J, Allard D, Hemmingson O, Tomasice G, et al. eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. Nature. 2014;513(7516):105–9.
14. Gintaras AC, Raught B, Sonenberg N. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Ann Rev Biochem. 1999;68:913–63.
15. Wiegner A, Uthe FW, Jameson T, Ruoss Y, Huettenrauch M, Kuespert M, et al. Targeting translation initiation bypasses signaling crosstalk...
mechanisms that maintain high MYC levels in colorectal cancer. Cancer Discov. 2015;5(7):768–81.
16. Spriggs KA, Cobbold LC, Jopling CL, Cooper RE, Wilson LA, Stoneley M, et al.Canonical initiation factor requirements of the MYC family of internal ribosome entry segments. Mol Cell Biol. 2009;29(6):1565–74.
17. Young P, Atkin CE, Zhou F, Gupta N, Hinnebusch AG, Lorsch JR. Yeast elf4A enhances recruitment of mRNAs regardless of their structural complexity. Elife. 2017;6:e31476.
18. Sodir NM, Swigart LB, Kamezis AN, Hanahan D, Evan GI, Soucek L. Endogenous Myc maintains the tumor microenvironment. Genes Dev. 2011;25(9):907–16.
19. Ischenko I, Zhi J, Moll UM, Nemajerova A, Petrenko O. Direct reprogramming by oncogenic Ras and Myc. Proc Natl Acad Sci U S A. 2013;110(10):3937–42.
20. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, et al. miR-9, a MYC/ MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol. 2010;12(3):247–56.
21. Khew-Goodall Y, Goodall GJ. Myc-modulated miR-9 makes more metastases. Nat Cell Biol. 2010;12(3):209–11.
22. Duffy MJ, O’Grady S, Tang M, Crown J. MYC as a target for cancer treatment. Cancer Treat Rev. 2021;94:102154.
23. Duffy MJ, Crown J. Drugging “undruggable” genes for cancer treatment: are we making progress? Int J Cancer. 2021;148(1):6–17.
24. Iwasaki S, Floor SN, Ingolia NT. Rocaglates convert DEAD-box protein eIF4A into a sequence-selective translational repressor. Nature. 2016;534(7608):558–61.
25. Wu Y, Giasi M, Kohler R, Chen WM, Krammer PH, Li-Weber M. Rocaglamide breaks TRAIL-resistance in human multiple myeloma and acute T-cell leukemia in vivo in a mouse xenograft model. Cancer Lett. 2017;389:70–7.
26. Luan Z, He Y, Alattar M, Chen ZS, He F. Targeting the prohibition scaffold-CRAF kinase interaction in RAS-ERK-driven pancreatic ductal adenocarcinoma. Mol Cancer. 2014;13:11.
27. Sakellariou D, Frankel LB. EIF4A3: a gatekeeper of autophagy. Autophagy. 2021. https://doi.org/10.1080/15548627.2021.1985881.
28. Wing X, Wang R, Bai S, Xiong S, Li Y, Liu M, et al. Musashi2 contributes to the maintenance of CD44v6+ liver cancer stem cells via notch1 signaling pathway. J Exp Clin Cancer Res. 2019;38(1):505.
29. Stellas D, Szabolcs M, Koul S, Li Z, Polyzos A, Anagnostopoulos C, et al. Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer. J Natl Cancer Inst. 2014;106(12):dju320.
30. Jackstadt R, Hermeking H. MicroRNAs as regulators and mediators of c-MYC function. Biochim Biophys Acta. 2015;1849(5):544–53.
31. Lin CJ, Cencic R, Mills JR, Robert F, Pelletier J. c-Myc and elf4A are components of a feedforward loop that links transcription and translation. Cancer Res. 2008;68(13):5326–34.
32. Dan C, Reddy ER, Shokat KM, Soucek L. Drugging the “undruggable” cancer targets. Nat Rev Cancer. 2017;17(8):522–8.
33. Boj SF, Hwang CJ, Baker LA, Chio IIC, Engle DD, Corbo V, et al. Organo- noid models of human and mouse ductal pancreatic cancer. Cell. 2015;160(1–2):324–8.
34. Pelletier J, Graff J, Ruggiero D, Sonenberg N. Targeting the elf4F translation initiation complex: a critical nexus for cancer development. Can Res. 2015;75(2):250–63.
35. Yao C, Ni Z, Gong C, Zhu X, Wang L, Xu Z, et al. Rocaglamide enhances NK cell-mediated killing of non-small cell lung cancer cells by inhibiting autophagy. Autophagy. 2018;14(10):1831–44.
36. Muller D, Shin S, Goulet de Rugy T, Samaan R, Baer R, Strehaiano M, et al. elf4A inhibition circumvents uncontrolled DNA replication mediated by 4E-BP1 loss in pancreatic cancer. JCI Insight. 2019. https://doi.org/10.1172/jci.insight.121951.
37. Chan K, Robert F, Oertlin C, Kapeller-Libermann D, Avizonis D, Gutierrez J, et al. elf4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma. Nat Commun. 2019;10:16.
38. Castell A, Larsson L-G. Targeting MYC translation in colorectal cancer. Cancer Discov. 2015;5(7):701–3.
39. Madden SK, de Araujo AD, Gerhardt M, Fairlie DP, Mason JM. Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc. Mol Cancer. 2021;20(1):3.
40. Luan Z, He Y, He F, Chen Z. Rocaglamide overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells by attenuating the inhibition of caspase-8 through cellular FLICE-like-inhibitory protein downregulation. Mol Med Rep. 2015;11(1):203–11.
41. Wang B, Li Y, Tan F, Xiao Z. Chinese herb derived-Rocaglamide A is a potent inhibitor of pancreatic cancer cells. Am J Transl Res. 2016;8(2):1047–54.
42. Doudican NA, Orlow SJ. Inhibition of the CRAF/prohibitin interaction reverses CRAF-dependent resistance to vemurafenib Oncogene. 2017;36(3):423–8.
43. Wu Y, Giasi M, Kohler R, Chen WM, Krammer PH, Li-Weber M. Rocaglamide breaks TRAIL-resistance in human multiple myeloma and acute T-cell leukemia in vivo in a mouse xenograft model. Cancer Lett. 2017;389:70–7.
44. Yurugi H, Marini F, Weber C, David K, Zhao Q, Binder H, et al. Targeting probiotics with chemical ligands inhibits KRAS-mediated lung tumours. Oncogene. 2017;36(33):4778–89.
45. Chang LS, Oblinger JL, Burns SS, Huang J, Anderson LW, Hollingshead MG, et al. Targeting protein translation by Rocaglamide and Didesmethylocaglamide to treat MPNST and other sarcomas. Mol Cancer Ther. 2020;19(3):731–41.